AJP - Endo Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 292: E1062-E1068, 2007. First published December 5, 2006; doi:10.1152/ajpendo.00450.2006
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow All Versions of this Article:
292/4/E1062    most recent
00450.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sloth, B.
Right arrow Articles by Astrup, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sloth, B.
Right arrow Articles by Astrup, A.

Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

Birgitte Sloth,1 Jens Juul Holst,2 Anne Flint,1 Nikolaj Ture Gregersen,1 and Arne Astrup1

1Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, Frederiksberg; and 2Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Submitted 25 August 2006 ; accepted in final form 4 December 2006

Peptide YY (PYY)3–36 has been shown to produce dramatic reductions in energy intake (EI), but no human data exist regarding energy expenditure (EE), glucose and fat metabolism. Nothing is known regarding PYY1-36. To compare effects of PYY1–36 and PYY3–36 on appetite, EI, EE, insulin, glucose and free fatty acids (FFA) concentrations, 12 lean and 12 obese males participated in a blinded, randomized, crossover study with 90-min infusions of saline, 0.8 pmol·kg–1·min–1 PYY1–36 and PYY3–36. Only four participants completed PYY3–36 infusions because of nausea. Subsequently, six lean and eight obese participants completed 0.2 pmol·kg–1·min–1 PYY3–36 and 1.6 pmol·kg–1·min–1 PYY1–36 infusions. PYY3–36 at 0.8 pmol·kg–1·min–1 produced reduced EI, lower ratings of well-being, increases in FFA, postprandial glucose (only 0.8 pmol·kg–1·min–1 PYY3–36) and insulin concentrations, as well as heart rate and EE (only 0.8 pmol·kg–1·min–1 PYY3–36). PYY1–36 at 1.6 pmol·kg–1·min–1 produced increased heart rate and postprandial insulin response. Ratings of appetite were opposite with infusions of 0.8 and 1.6 pmol·kg–1·min–1 PYY1–36 and seemed to depend on subjects being lean or obese. PYY3–36 caused increased thermogenesis, lipolysis, postprandial insulin and glucose responses, suggestive of increased sympathoadrenal activity. PYY1–36 had no effect on EI and no clear effects on appetite but resulted in increased heart rate and postprandial insulin response. However, highest tolerable dose of PYY1–36 was probably not reached in the present study.

Peptide YY; free fatty acids; insulin sensitivity; arcuate nucleus; neuropeptide Y receptors



Address for reprint requests and other correspondence: B. Sloth, Dept. of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, 30 Rolighedsvej, DK-1958 Frederiksberg C, Denmark (e-mail: bsl{at}life.ku.dk)




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
D. A. Van Vugt
Brain imaging studies of appetite in the context of obesity and the menstrual cycle
Hum. Reprod. Update, November 19, 2009; (2009) dmp051v1.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
E. Karra, K. Chandarana, and R. L. Batterham
The role of peptide YY in appetite regulation and obesity
J. Physiol., January 1, 2009; 587(1): 19 - 25.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle
The Obesity Epidemic: Pharmacological Challenges
Mol. Interv., April 1, 2008; 8(2): 82 - 98.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. H. Tschop and E. Ravussin
Peptide YY: obesity's cause and cure?
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1131 - E1133.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Sloth, L. Davidsen, J. J. Holst, A. Flint, and A. Astrup
Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males
Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E604 - E609.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger
Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R39 - R46.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.